a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy (ADOA)…
Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced clinical data for IAM1363, a brain-penetrant HER2 small-molecule tyrosine kinase inhibitor (TKI), which showed anti-tumor activity in heavily pretreated…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for…
the AI precision oncology company behind the Polaris™ platform, today announced its selection for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program. This engagement will provide StratifAI with access to MSK’s extensive clinical datasets and the opportunity to…
(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met…
Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, in patients with advanced HER2+…
Aurion Biotech Reports Positive 12-Month Results from Phase 1/2 CLARA Trial of AURN001 in Corneal Endothelial Disease Aurion Biotech, a clinical-stage regenerative medicine company dedicated to restoring vision for millions of patients worldwide, today announced encouraging 12-month results from its…
Ono Pharmaceutical Announces Two-Year Results from Phase 3 MOTION Study of Vimseltinib in TGCT at ESMO 2025 Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that two-year efficacy and safety results from the…
Evvy, the world’s leading platform leveraging the vaginal microbiome to improve women’s health outcomes, today announced record growth and compelling new data demonstrating the transformative impact of its platform. Evvy now serves over 75,000 patients and partners with more than…
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term results from the global Phase 3 MANEUVER trial, evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor, for the treatment…